News | Patient Positioning Radiation Therapy | September 05, 2017

Medicare beneficiaries in North Carolina, South Carolina, Virginia and West Virginia will have access to spacer hydrogel for prostate cancer radiotherapy beginning Oct. 2

Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel

September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina, South Carolina, Virginia and West Virginia — will establish coverage for SpaceOAR hydrogel when medically necessary, effective Oct. 2, 2017. The change will enable Medicare beneficiaries in these states access to SpaceOAR hydrogel for use in prostate cancer radiotherapy.

Palmetto posted a revision to its Local Coverage Determination (LCD) Non-Covered Category III CPT Codes (L34555) deleting American Medical Association (AMA) CPT code 0438T, Transperineal placement of biodegradable material, indicating that this is now a covered procedure effective 10/02/2017. Currently, AMA CPT code 0438T is typically the AMA CPT code used to report the SpaceOAR hydrogel procedure.

SpaceOAR hydrogel reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate. This space between organs decreases the radiation dose to the rectum and other organs at risk (OAR). Earlier this year, Augmenix announced published data from their prospective, randomized clinical trial showing that patients treated with SpaceOAR hydrogel prior to prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary and sexual benefit through three years of follow-up.

In November 2016, the AMA created a new Category I CPT Code for the SpaceOAR hydrogel procedure that will become effective on Jan. 1, 2018. The new code will replace AMA CPT code 0438T.

Read the article "Augmenix Announces Positive Three-Year Long-Term Data for SpaceOAR Hydrogel Spacer"

For more information: www.augmenix.com


Related Content

News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Radiation Therapy

February 8, 2024 — RaySearch Laboratories AB announced that The Royal Marsden NHS Foundation Trust, a specialist cancer ...

Time February 08, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
News | Artificial Intelligence

January 25, 2024 — Digital pathology has both sped up and increased the accuracy of cancer diagnosis over the past 10 ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Subscribe Now